ArticleAdvanced healthcare materials2023
175 Years of Bilirubin Testing: Ready for Point-of-Care?
Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of bilirubin as a biomarker of rheumatic diseases: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Effects of Gilbert syndrome on cardiovascular disease risk reduction: a systematic review.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Assessing Diagnostic Accuracy of a Handheld Point-of-Care Device for Quantifying Neonatal Bilirubin Levels: The BEAT Jaundice @Home Study.Neonatology · 2026Article
- Article
- Bilirubin Sensing Using Organic Electrochemical Transistors: Role of Gate Materials and Operational Parameters.Advanced healthcare materials · 2025Article
- A metabolite-based resistance mechanism against malaria.Science (New York, N.Y.) · 2025Article
- Copper and nickel doped carbon dots for rapid and sensitive fluorescent turn-off detection of bilirubin.Scientific reports · 2025Article
- Development of a Polymersome Blood Ammonia Assay Coupled with a Portable Near-Infrared Fluorometer.ACS bio & med chem Au · 2024Article
- Wound pH-Modulating Strategies for Diabetic Wound Healing.Advances in wound care · 2024Review
- 175 Years of Bilirubin Testing: Ready for Point-of-Care?Advanced healthcare materials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilirubin was first detected in blood in 1847 and since then has become one of the most widely used biomarkers for liver disease. Clinical routine bilirubin testing is performed at the hospital laboratory, and the gold standard colorimetric test is prone to interferences. The absence of a bedside test for bilirubin delays critical clinical decisions for patients with liver disease. This clinical care gap has motivated the development of a new generation of bioengineered point-of-care bilirubin assays. In this Perspective, recently developed bilirubin assays are critically discussed, and their translational potential evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.